2022年肝脏会议-美国肝病研究协会(AASLD)。第73届年会。华盛顿特区——2022年11月4日至8日

IF 0.2 4区医学 Q4 Medicine

Drugs of The Future Pub Date : 2023-01-01 DOI:10.1358/dof.2023.48.2.3521855

J. Gavazzi

{"title":"2022年肝脏会议-美国肝病研究协会(AASLD)。第73届年会。华盛顿特区——2022年11月4日至8日","authors":"J. Gavazzi","doi":"10.1358/dof.2023.48.2.3521855","DOIUrl":null,"url":null,"abstract":"The Liver Meeting-the American Association for the Study of Liver Diseases (AASLD) 2022 annual meeting-returned to in-person attendance for the first time in 2 years since the COVID-19 public health emergency began and included a virtual option. Comprised of scientists and healthcare profession-als, AASLD is the leading organization committed to preventing and curing liver disease. The \"hottest meeting in hepatology, \" according to the AASLD, included plenary sessions, presenta-tions and over 4,800 scientific s highlighting the latest scientific advancements in the field of hepatology. Research and clinical trial updates were provided in many specific liver disease areas, including hepatitis, fibrosis, nonalcoholic fatty liver disease, cirrhosis, nonalcoholic steatohepatitis, trans-plantation, and so on. Along with groundbreaking research in hepatology, many presentations included the impact of COVID-19 on patients with these diseases. This report highlights a selec-tion of presentations about treatment updates provided during the conference.","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Liver Meeting 2022 - American Association for the Study of Liver Diseases (AASLD). 73rd Annual Meeting. Washington, D.C. - November 4-8, 2022\",\"authors\":\"J. Gavazzi\",\"doi\":\"10.1358/dof.2023.48.2.3521855\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The Liver Meeting-the American Association for the Study of Liver Diseases (AASLD) 2022 annual meeting-returned to in-person attendance for the first time in 2 years since the COVID-19 public health emergency began and included a virtual option. Comprised of scientists and healthcare profession-als, AASLD is the leading organization committed to preventing and curing liver disease. The \\\"hottest meeting in hepatology, \\\" according to the AASLD, included plenary sessions, presenta-tions and over 4,800 scientific s highlighting the latest scientific advancements in the field of hepatology. Research and clinical trial updates were provided in many specific liver disease areas, including hepatitis, fibrosis, nonalcoholic fatty liver disease, cirrhosis, nonalcoholic steatohepatitis, trans-plantation, and so on. Along with groundbreaking research in hepatology, many presentations included the impact of COVID-19 on patients with these diseases. This report highlights a selec-tion of presentations about treatment updates provided during the conference.\",\"PeriodicalId\":11366,\"journal\":{\"name\":\"Drugs of The Future\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drugs of The Future\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1358/dof.2023.48.2.3521855\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs of The Future","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1358/dof.2023.48.2.3521855","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

肝脏会议——美国肝病研究协会(AASLD) 2022年年会——自COVID-19突发公共卫生事件开始两年来首次恢复了现场出席，并包括了一个虚拟选项。AASLD由科学家和医疗保健专业人员组成，是致力于预防和治疗肝脏疾病的领先组织。根据AASLD的说法，“肝病学最热门的会议”包括全体会议、演讲和4800多名科学家，重点介绍了肝病学领域的最新科学进展。提供了许多特定肝病领域的研究和临床试验更新，包括肝炎、纤维化、非酒精性脂肪性肝病、肝硬化、非酒精性脂肪性肝炎、移植等。除了肝病学方面的突破性研究外，许多演讲还包括COVID-19对这些疾病患者的影响。本报告重点介绍了会议期间提供的有关治疗更新的报告。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The Liver Meeting 2022 - American Association for the Study of Liver Diseases (AASLD). 73rd Annual Meeting. Washington, D.C. - November 4-8, 2022

The Liver Meeting-the American Association for the Study of Liver Diseases (AASLD) 2022 annual meeting-returned to in-person attendance for the first time in 2 years since the COVID-19 public health emergency began and included a virtual option. Comprised of scientists and healthcare profession-als, AASLD is the leading organization committed to preventing and curing liver disease. The "hottest meeting in hepatology, " according to the AASLD, included plenary sessions, presenta-tions and over 4,800 scientific s highlighting the latest scientific advancements in the field of hepatology. Research and clinical trial updates were provided in many specific liver disease areas, including hepatitis, fibrosis, nonalcoholic fatty liver disease, cirrhosis, nonalcoholic steatohepatitis, trans-plantation, and so on. Along with groundbreaking research in hepatology, many presentations included the impact of COVID-19 on patients with these diseases. This report highlights a selec-tion of presentations about treatment updates provided during the conference.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Drugs of The Future 医学-药学

CiteScore

0.30

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： A leading international, peer-reviewed biomedical research journal publishing articles on topics emerging from the confluence of fields including chemistry, biology, pharmacology, genomics and medicine, and addressed to scientists and researchers involved in drug design, discovery and development, target identification and validation, and the preclinical and clinical development of treatments for common as well as rare and neglected diseases and conditions. The journal publishes monographs containing comprehensive product information on new compounds in development, including synthesis, preclinical pharmacology, pharmacokinetics and metabolism, safety, clinical studies and drug interactions, as well as review articles on a variety of topics, congress and meeting reports.